A Type 2 diabetes drug, developed by Merck & Co. and Pfizer, won FDA approval Dec. 19., according to Reuters.
Here are three things to know
1. The drug, Steglatro, is a SGLT2 inhibitor, which works by causing patients with Type 2 diabetes to rid glucose through their urine.
2. The oral drug enters the market as a competitor to AstraZeneca's Farxiga, Johnson & Johnson’s Invokana and Eli Lilly and Boehringer Ingelheim’s Jardiance.
3. The FDA granted Steglatro approval as both a single-therapy or a fixed-dose combination therapy with Merck's already-approved diabetes drug Januvia or metformin, which is an older generic version of a diabetes drug.